Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label study of safety, tolerability, pharmacokinetics and pharmacodynamics of
Auriхim multiple doses in patients with recurrent/ refractory В-cell, CD20-positive
non-Hodgkin lymphoma of low tumor grade or with follicular lymphoma, as well as in patients
non-treated before for В-cell, CD20-positive non-Hodgkin lymphoma of low tumor grade.
The study will be carried out in 4-6 Russian and Belarussian sites. The study will be
consisted of screening period, induction (obligatory) phase and supporting (non-obligatory)
phase of the investigational therapy and post-treatment follow-up period.